The certification covers the company’s manufacturing facility for cephalosporin, carbapenem, and lyophilized injectable oncology formulations. Shares of Venus Remedies Ltd ended at ₹296.20, down by ₹3.35, or 1.12%, on the BSE.

The certification covers the company’s manufacturing facility for cephalosporin, carbapenem, and lyophilized injectable oncology formulations. Shares of Venus Remedies Ltd ended at ₹296.20, down by ₹3.35, or 1.12%, on the BSE.
+91 888 718 7394